ReviewMedical oncology (Northwood, London, England)2025
A comprehensive review on the role of acetamido as a linker for the design and discovery of anticancer agents.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasminogen activator inhibitor-1 as an oncologic target: biology, therapeutic inhibitors, and clinical translation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the most significant health problem for mankind, causing millions of deaths every year. After the discovery of chemotherapy, conventional treatments have rapidly developed drug resistance, which has led to the search for novel and more effective anticancer agents. Different linkers have played a crucial role in the design of drugs due to their improved selectivity, physicochemical properties, and therapeutic efficacy. Among these linkers, the acetamido linker has emerged as a promising strategic pathway for enhancing the anticancer potency of drug candidates. Introducing an acetamido linker into the molecular scaffold strategically enhances the pharmacokinetics, stability, and selectivity of anticancer drugs, thus making it more precisely targeted to tumor cells. Acetamido groups have been reported to modulate the interaction between the drug and its molecular targets, enhancing cytotoxicity against a range of cancer cell lines, including different cancer traits. This review discusses the emerging role of acetamido linkers in anticancer drug design, focusing on SAR analysis and their therapeutic effects based on IC
Indexed as
Identifiers
41003852What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.